MedPage Today on MSN
Among IL-1 Inhibitors for Treating VEXAS, This One Stands Out
Canakinumab (Ilaris) may be the better option than anakinra (Kineret) when treating the rare disease called VEXAS syndrome ...
Recently, BAIC Foton submitted a patent for battery anomaly sampling recognition, with publication number CN120686136A. This technology analyzes the voltage data of multiple battery cells and uses the ...
Exploration Target: Sulista covers a vast ‘10 km by 2 km’ exploration target area returning shallow, high-grade rare earth ...
WisdomTree Europe Hedged Equity Fund ETF offers exposure to European equities while hedging euro/dollar currency risk. Read ...
Prepare for your fantasy hockey draft with these defensemen in the right situation to have a break out season.
This study provides valuable insights with solid evidence into altered tactile perception in a mouse model of ASD (Fmr1 mice), paralleling sensory abnormalities in Fragile X and autism. Its main ...
Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...
Researchers have discovered in a new study that patients with age-related eye diseases (AREDs) have a significantly increased ...
Brazilian Rare Earths Limited (ASX: BRE / OTCQX: BRELY) (BRE) announces exploration results at the Sulista Project, located ...
Beta-blocker therapy reduced the risk of death or major adverse cardiovascular events by 15% in patients with MI and a LVEF ...
Data derived from Freedman A, et al. Abstract #102. Presented at: American Heart Association’s Hypertension Scientific ...
The overall, downward trend in the minimum extent from 1979 to 2025 is 12.1 percent per decade relative to the 1981 to 2010 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results